A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Recruiting · Phase 3 · NCT06937229
Conditions: Alzheimer Disease, Agitation
At a glance
- Research payments reported, 2025
- $34,269
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 650
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- KarXT (drug), KarX-EC (drug)
- Dates
- Started 2025-12-02; completion 2029-07-20
- Results posted
- Not yet
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
From ClinicalTrials.gov, last updated 2026-10-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $34,269 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Alliance Clinical West Hills $34,184
- Sunwise Clinical Research $85
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.